Observational analysis shows arachidonic acid mitigates liver and kidney injury in rats induced by thioacetamide, suggesting potential therapeutic benefits.
Arachidonic acid (ArA) is an essential omega-6 polyunsaturated fatty acid is crucial in various physiological processes and disease conditions. Nevertheless, the effects of arachidonic acid on liver and kidney damage are not well understood. Therefore, this study aimed to explore the beneficial role of ArA on liver and kidney injuries caused by thioacetamide (TAA) in rats, focusing on the associated hematological changes.The six groups, each consisting of 10 rats, are as follows; Control, 30 mg/kg ArA-treated, 20 mg/kg TAA-induced liver injury, ArA (10, 20, and 30 mg/kg)-pre-treated liver injury groups.The pre-treatment of ArA ameliorated histopathological injuries of hepatic and kidney tissues and hepatic dysfunction in TAA-treated rats. TAA increased hepatic and kidney injury serum biomarkers, otherwise, ArA significantly suppressed increased levels of these parameters and inhibited metabolic acidosis and dehydration due to TAA treatment. Besides, ArA effectively preserved protein and cholesterol metabolism against TAA-induced hepatic injury. ArA suppressed TAA caused ionic imbalance. Notably, the highest AA dosage (30 mg/kg) provided the most protective effects against TAA-induced liver and kidney damage.This study demonstrated that ArA effectively reduces liver and kidney injuries caused by TAA, indicating its potential as a promising preventive or therapeutic approach.
No takes yet. Share an insight, caveat, or question.
Xiang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: